Peptide-based MRI contrast agent and near-infrared fluorescent probe for intratumoral legumain detection

Biomaterials

Volumn 35, Issue 1, 2014, Pages 304-315

  Chen, Yu Jen ^a   Wu, Shou Cheng ^a   Chen, Chung Yung ^b   Tzou, Shey Cherng ^a   Cheng, Tian Lu ^c   Huang, Ying Fang ^a   Yuan, Shyng Shiou ^d   Wang, Yun Ming ^a,c  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Contrast agent; Legumain; MRI; Optical imaging

Indexed keywords

CONTRAST AGENT; FLUORESCENCE STUDIES; LEGUMAIN; MRI CONTRAST AGENTS; NEAR-INFRARED FLUORESCENT; OPTICAL IMAGING; ROTATIONAL CORRELATION TIME; SUBSTRATE PEPTIDES;

DIAGNOSIS; FLUORESCENCE; GADOLINIUM COMPOUNDS; MAGNETIC RESONANCE IMAGING; OPTICAL IMAGE STORAGE; PEPTIDES; PROBES; TUMORS;

INFRARED DEVICES;

LEGUMAIN; NBCB TTDA LEG(D) GADOLINIUM; NBCB TTDA LEG(L) GADOLINIUM; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE IMAGING; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTON; PRIORITY JOURNAL;

CONTRAST AGENT; LEGUMAIN; MRI; OPTICAL IMAGING;

ANIMALS; CONTRAST MEDIA; CYSTEINE ENDOPEPTIDASES; FLUORESCENT DYES; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PEPTIDES; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, NEAR-INFRARED;

EID: 84887017138     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.100     Document Type: Article

References (39)

1. Voisin P., Ribot E.J., Miraux S., Bouzier-Sore A.K., Lahitte J.F., Bouchaud V., et al. Use of lanthanide-grafted inorganic nanoparticles as effective contrast agents for cellular uptake imaging. Bioconjug Chem 2007, 18:1053-1063.
2. Frullano L., Meade T.J. Multimodal MRI contrast agents. JBiol Inorg Chem 2007, 12:939-949.
3. 3+ nanospheres as anticancer drug carrier and MRI contrast agent. Langmuir 2013, 29:1286-1294.
4. Choy G., O'Connor S., Diehn F.E., Costouros N., Alexander H.R., Choyke P., et al. Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. BioTechniques 2003, 35:1022-1030.
5. 3 integrin for tumor imaging. Bioconjug Chem 2002, 13:561-570.
6. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004, 15:61-69.
7. Juran S., Walther M., Stephan H., Bergamann R., Stainbach J., Kraus W., et al. Hexadentate bispidine derivatives as versatile bifunctional chelate agents for copper(II) radioisotopes. Bioconjug Chem 2009, 20:347-359.
8. 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem 2009, 20:1016-1025.
9. Zhang H., Schuhmacher J., Waser B., Wild D., Eisenhut M., Reubi J.C., et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging 2007, 34:1198-1208.
10. 64Cu-labeled RGD-bombesin heterodimer. JNucl Med 2009, 50:1168-1177.
11. Weissleder R., Mahmood U. Molecular imaging. Radiology 2001, 219:316-333.
12. Xie H., Zhu Y., Jiang W., Zhou Q., Yang H., Gu N., et al. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma invivo. Biomaterials 2011, 32:495-502.
13. 1 magnetic resonance imaging contrast agent. Angew Chem Int Ed 2010, 49:346-350.
14. 3 in brain tumor xenografts. Cancer Res 2004, 64:8009-8014.
15. Kim S., Lim Y.T., Soltesz E.G., De Grand A.M., Lee J., Nakayama A., et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004, 22:93-97.
16. Colak S.B., van der Mark M.B., Hooft G.W., Hoogengraad J.H., van der Linden E.W., Kuijpers F.A. Clinical optical tomography and NIR spectroscopy for breast cancer detection. IEEE J Sel Top Quantum Electron 1999, 5:1143-1158.
17. Weissleder R., Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003, 9:123-128.
18. Weissleder R. Aclearer vision for invivo imaging. Nat Biotechnol 2001, 19:316-317.
19. Tung C.H. Fluorescent peptide probes for invivo diagnostic imaging. Biopolymers 2004, 76:391-403.
20. Rao J., Dragulescu-Andrasi A., Yao H. Fluorescence imaging invivo: recent advances. Curr Opin Biotechnol 2007, 18:17-25.
21. Artemov D., Mori N., Ravi R., Bhujwalla Z.M. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003, 63:2723-2727.
22. Artemov D., Mori N., Okollie B., Bhujwalla Z.M. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003, 49:403-408.
23. Wrensch M., Minn Y., Chew T., Bondy M., Berger M.S. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncology 2002, 4:278-299.
24. Parsons S.L., Watson S.A., Steele R.J. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997, 23:526-531.
25. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. JClin Oncol 2000, 18:1135-1149.
26. Chiappori A.A., Eckhardt S.G., Bukowski R., Sullivan D.M., Ikeda M., Yano Y., et al. Aphase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 2007, 13:2091-2099.
27. Beattie G.J., Smyth J.F. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998, 4:1899-1902.
28. 2+ by 3, 6, 10-tri (carboxymethyl)-3, 6, 10-triazadodecanedioic acid. Dalton Trans 1998, 24:4113-4118.
29. Lee J., Bogyo M. A bright approach to the immunoproteasome: Development of LMP2/β1i-specific imaging probes. Bioorg Med Chem Lett 2012, 22:1340-1343.
30. van Eijk M., Johannes C., van Noorden F., de Groot C. Proteinases and their inhibitors in the immune system. Int Rev Cytol 2003, 222:197-236.
31. Chen J.M., Fortunato M., Stevens R.A., Barrett A.J. Inhibition of distant caspase homologues by natural caspase inhibitors. Biol Chem 2001, 382:777-783.
32. Shirahama-Noda K., Yamamoto A., Sugihara K., Hashimoto N., Asano M., Nishimura M., Hara-Nishimura I. Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J Biol Chem 2003, 278:33194-33199.
33. Sarandeses C.S., Covelo G., Diaz-Jullien C., Freire M. Prothymosin α is processed to thymosin α1 and thymosin α11 by a lysosomal asparaginyl endopeptidase. JBiol Chem 2003, 278:13286-13293.
34. Morita Y., Araki H., Sugimoto T., Takeuchi K., Yamane T., Maeda T., et al. Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells. FEBS Lett 2007, 7:1417-1424.
35. Lin Y.H., Dayananda K., Chen C.Y., Liu G.C., Luo T.Y., Hsu H.S., et al. Invivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5. 5. Bioorg Med Chem 2011, 19:1085-1096.
36. Kaiser E., Colescott R.L., Bossinger C.D., Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 1970, 34:595-598.
37. Hilderbrand S.A., Kelly K.A., Weissleder R., Tung C.H. Monofunctional near-infrared fluorochromes for imaging applications. Bioconjug Chem 2005, 16:1275-1281.
38. 2- derivatives. Inorg Chem 2011, 50:1275-1287.
39. Johansson M.K., Cook R.M. Intramolecular dimers: a new design strategy for fluorescence-quenched probes. Chem Eur J 2003, 9:3466-3471.